Previous close | 180.87 |
Open | 176.50 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1200 |
Day's range | 173.80 - 180.21 |
52-week range | 115.03 - 217.25 |
Volume | |
Avg. volume | 5,166,875 |
Market cap | 67.639B |
Beta (5Y monthly) | 1.71 |
PE ratio (TTM) | 6.64 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment. The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline. As a result, Moderna could launch other potential blockbusters over the next few years.
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.